



**ASX RELEASE
14 June 2012**

Tissue Therapies Limited (ASX Code: TIS)- Change of Director's Interest Notice

The Appendix 3Y – Change of Director's Interest Notice is lodge as an error. It was identical to the one that was lodged on 30 May 2011. There is no change in Director's Interest Notice for Mr Greg Baynton.

About Tissue Therapies Limited

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue repair, cell culture and other applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a technology developed by cell biology, tissue engineering and protein engineering experts at the Institute for Health and Biomedical Innovation (IHBI) at the Queensland University of Technology (QUT) for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, cell based therapies and other cell culture uses.

Based on its VitroGro® technology, Tissue Therapies is developing more effective treatments for acute and chronic wound healing applications including chronic skin ulcers and burns.

Tissue Therapies is also proceeding with the development of other commercial applications for VitroGro® and other technologies for the treatment of psoriasis, scar prevention and treatment and potential treatments for various cancers including those of the breast, colon and prostate.

VitroGro® also provides a fundamental, transforming technology for completely defined cell culture reagents (ie. containing no purified animal or human proteins) to sustain and enhance the growth of live cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

More information: www.tissuetherapies.com

Tissue Therapies Limited ABN 45 101 955 088 www.tissuetherapies.com
Level 19, 179 Turbot Street
Brisbane QLD 4000 Australia
GPO Box 1596 Brisbane Qld 4001
telephone +61 7 3334 3900 facsimile +61 7 3334 3999